(ANGO) AngioDynamics - Ratings and Ratios

AngioDynamics, Inc. (NASDAQ:ANGO) is a medical technology company specializing in the design, manufacture, and sale of innovative medical devices used in the treatment of peripheral vascular disease, oncology, and surgical settings. The companys product portfolio includes the Auryon Atherectomy system, designed to optimize wavelength, pulse width, and amplitude for effective lesion removal while preserving the vessel wall endothelium. Their thrombus management solutions feature the AlphaVac mechanical thrombectomy system, which eliminates the need for perfusionist support, and thrombolytic catheters for delivering clot-dissolving agents in various vascular accesses. Additionally, the AngioVac system provides extracorporeal circulatory support for up to six hours, including a pump, filter, and reinfusion cannula for venous drainage during bypass procedures.

The company also offers the NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for soft tissue treatment, and a range of peripheral products such as angiographic catheters, guidewires, and drainage catheters. Their micro-access kits enable minimally invasive procedures with smaller introducer systems, while the VenaCure EVLT system is used in endovascular laser treatments for superficial venous disease. The Solero MTA System includes a microwave generator and applicators for tumor treatment. Founded in 1988, AngioDynamics is headquartered in Latham, New York, and operates globally.

Based on the provided data, the 3-month forecast for AngioDynamics (NASDAQ:ANGO) suggests potential resistance around the SMA20 and SMA50 levels of $10.65 and $10.60, respectively. Support may be found near the SMA200 level of $7.82. The Average True Range (ATR) of 0.62 indicates moderate volatility, with expected price fluctuations within a $1.86 range over the next three months. The high forward P/E ratio of 96.15 reflects investor expectations for future growth, though the current P/E of 0 raises concerns about profitability. The stocks performance will likely hinge on its ability to meet these growth expectations and improve its earnings trajectory.